Human BioSystems Appoints Gary Harris to its Advisory Board

Business Wire, Sept 13, 2005

PALO ALTO, Calif. -- Human Biosystems (OTCBB:HBSC) announces today the appointment of Gary Harris to its Advisory Board. "Mr. Harris brings a wide range of business expertise to HBS, from investment banking to corporate alliances and mergers and acquisitions," according to HBS CEO Harry Masuda.

"As we look toward strategic alliances and licensing of our technology to leverage our resources, Mr. Harris will be an invaluable addition to our Advisory Board," continued Mr. Masuda.

Mr. Harris was a former partner in Woodside Capital Partners, a boutique investment banking firm, the Director of Mergers and Acquisitions and Corporate Alliances for Adobe Systems, Inc., Director of Business Development for Sharp Corporation International Group, and held the position of Senior Manager, Corporate Business Development Office of the Xerox Corporation, in addition to numerous other senior management positions during the past 30 years.

His accomplishments include the successful acquisition of more than 10 companies and corporate partnerships resulting in combined revenues in excess of $6.5 Billion. He has negotiated OEM sales, technology development and licensing agreements and joint ventures with major business partners throughout Europe, Asia and the U.S.

Mr. Harris serves on the Board of the Kollage Community School of the Arts as its President, and is Chairman of the Notre Dame de Namur University-School of Sciences - Advisory Board and Chairman of its Computer Science Advisory Committee. He has also been a member of the City Council and Mayor of the City of Belmont, California, and has served on the Boards of South County Fire Authority, and Ahead Technology, Inc.

Mr. Harris received his BS and MS degrees in Physics from the University of Akron (Ohio).

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are ''forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the ability of the Company to fund marketing and sales efforts that may be required to effectively sell its products .and other factors discussed in filings made by the Company with the Securities and Exchange Commission

Human BioSystems (OTC Bulletin Board:HBSC)